Overview Dividends

(DXCM) DexCom - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074

Glucose, Monitor, Sensor, Transmitter, App

Health Care Equipment
Market Cap in USD: 26,094m
IPO / Inception: 2005-04-14
Return 12m vs S&P 500: -25.5%

EPS (Earnings per Share)

EPS (Earnings per Share) of DXCM over the last years for every Quarter: "2020-12": 0.23, "2021-03": 0.08, "2021-06": 0.19, "2021-09": 0.22, "2021-12": 0.17, "2022-03": 0.08, "2022-06": 0.17, "2022-09": 0.28, "2022-12": 0.34, "2023-03": 0.17, "2023-06": 0.34, "2023-09": 0.5, "2023-12": 0.5, "2024-03": 0.32, "2024-06": 0.43, "2024-09": 0.45, "2024-12": 0.38, "2025-03": 0.32, "2025-06": 0.48, "2025-09": 0.61, "2025-12": 0,
EPS CAGR: -27.58%
EPS Trend: 33.6%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of DXCM over the last years for every Quarter: 2020-12: 568.9, 2021-03: 505, 2021-06: 595.1, 2021-09: 650.2, 2021-12: 698.2, 2022-03: 628.8, 2022-06: 696.2, 2022-09: 769.6, 2022-12: 815.2, 2023-03: 741.5, 2023-06: 871.3, 2023-09: 975, 2023-12: 1034.5, 2024-03: 921, 2024-06: 1004.3, 2024-09: 994.2, 2024-12: 1113.5, 2025-03: 1036, 2025-06: 1157.1, 2025-09: 1209.3, 2025-12: null,
Rev. CAGR: 15.77%
Rev. Trend: 94.7%
Last SUE: 1.47
Qual. Beats: 3

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 45.5%
Value at Risk 5%th 60.5%
Relative Tail Risk -19.19%
Reward TTM
Sharpe Ratio -0.16
Alpha -31.52
CAGR/Max DD -0.21
Character TTM
Hurst Exponent 0.463
Beta 1.009
Beta Downside 1.110
Drawdowns 3y
Max DD 60.95%
Mean DD 29.06%
Median DD 36.57%

Description: DXCM DexCom December 17, 2025

DexCom, Inc. (NASDAQ:DXCM) designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management worldwide, selling directly to endocrinologists, physicians, and diabetes educators. Its flagship products include the G6 and G7 integrated CGM systems, the Dexcom Share remote-monitoring platform, the Real-Time API for third-party app integration, the ONE sensor aimed at replacing finger-stick testing, and the over-the-counter Stelo biosensor for pre-diabetes and Type 2 diabetes. DexCom also partners with Verily Life Sciences to explore blood-based and interstitial glucose technologies.

Key recent metrics: FY 2023 revenue reached approximately $3.2 billion, with the CGM segment growing at a ~12% CAGR, and DexCom holding roughly 30% of the U.S. CGM market share. In Q2 2024 the company reported $840 million in revenue and GAAP EPS of $0.96, beating consensus estimates. Sector drivers include rising global diabetes prevalence (projected >700 million patients by 2045), expanding payer reimbursement for CGM, and accelerating digital-health integration that fuels demand for APIs and remote-monitoring solutions.

For a deeper dive into DexCom’s valuation dynamics and how they compare to peers, you might find ValueRay’s analytical tools useful.

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (720.7m TTM) > 0 and > 6% of Revenue (6% = 271.0m TTM)
FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 41.71% (prev 63.94%; Δ -22.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.19 (>3.0%) and CFO 1.45b > Net Income 720.7m (YES >=105%, WARN >=100%)
Net Debt (685.3m) to EBITDA (1.22b) ratio: 0.56 <= 3.0 (WARN <= 3.5)
Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (407.4m) change vs 12m ago -0.68% (target <= -2.0% for YES)
Gross Margin 59.01% (prev 61.68%; Δ -2.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 65.19% (prev 62.23%; Δ 2.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 51.47 (EBITDA TTM 1.22b / Interest Expense TTM 19.0m) >= 6 (WARN >= 3)

Altman Z'' 4.03

(A) 0.25 = (Total Current Assets 5.22b - Total Current Liabilities 3.34b) / Total Assets 7.50b
(B) 0.29 = Retained Earnings (Balance) 2.17b / Total Assets 7.50b
(C) 0.14 = EBIT TTM 978.0m / Avg Total Assets 6.93b
(D) 0.47 = Book Value of Equity 2.25b / Total Liabilities 4.77b
Total Rating: 4.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 85.25

1. Piotroski 7.50pt
2. FCF Yield 4.20%
3. FCF Margin 23.51%
4. Debt/Equity 0.92
5. Debt/Ebitda 0.56
6. ROIC - WACC (= 7.32)%
7. RoE 29.82%
8. Rev. Trend 94.71%
9. EPS Trend 33.63%

What is the price of DXCM shares?

As of January 09, 2026, the stock is trading at USD 70.10 with a total of 5,080,494 shares traded.
Over the past week, the price has changed by +5.62%, over one month by +6.83%, over three months by +6.16% and over the past year by -11.66%.

Is DXCM a buy, sell or hold?

DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.
  • Strong Buy: 17
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the DXCM price?

Issuer Target Up/Down from current
Wallstreet Target Price 85.3 21.6%
Analysts Target Price 85.3 21.6%
ValueRay Target Price 65.6 -6.5%

DXCM Fundamental Data Overview January 05, 2026

Market Cap USD = 26.09b (26.09b USD * 1.0 USD.USD)
P/E Trailing = 36.9667
P/E Forward = 26.455
P/S = 5.7783
P/B = 9.4954
P/EG = 0.8727
Beta = 1.515
Revenue TTM = 4.52b USD
EBIT TTM = 978.0m USD
EBITDA TTM = 1.22b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.23b USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 685.3m USD (from netDebt column, last quarter)
Enterprise Value = 25.29b USD (26.09b + Debt 2.52b - CCE 3.32b)
Interest Coverage Ratio = 51.47 (Ebit TTM 978.0m / Interest Expense TTM 19.0m)
FCF Yield = 4.20% (FCF TTM 1.06b / Enterprise Value 25.29b)
FCF Margin = 23.51% (FCF TTM 1.06b / Revenue TTM 4.52b)
Net Margin = 15.96% (Net Income TTM 720.7m / Revenue TTM 4.52b)
Gross Margin = 59.01% ((Revenue TTM 4.52b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 60.48% (prev 59.53%)
Tobins Q-Ratio = 3.37 (Enterprise Value 25.29b / Total Assets 7.50b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.52b)
Taxrate = 19.44% (68.5m / 352.3m)
NOPAT = 787.8m (EBIT 978.0m * (1 - 19.44%))
Current Ratio = 1.56 (Total Current Assets 5.22b / Total Current Liabilities 3.34b)
Debt / Equity = 0.92 (Debt 2.52b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 0.56 (Net Debt 685.3m / EBITDA 1.22b)
Debt / FCF = 0.65 (Net Debt 685.3m / FCF TTM 1.06b)
Total Stockholder Equity = 2.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 720.7m / Total Assets 7.50b)
RoE = 29.82% (Net Income TTM 720.7m / Total Stockholder Equity 2.42b)
RoCE = 26.74% (EBIT 978.0m / Capital Employed (Equity 2.42b + L.T.Debt 1.24b))
RoIC = 16.21% (NOPAT 787.8m / Invested Capital 4.86b)
WACC = 8.89% (E(26.09b)/V(28.62b) * Re(9.73%) + D(2.52b)/V(28.62b) * Rd(0.19%) * (1-Tc(0.19)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.03%
[DCF Debug] Terminal Value 76.16% ; FCFE base≈851.1m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 58.02 (DCF Value 22.63b / Shares Outstanding 390.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 33.63 | EPS CAGR: -27.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 15.77% | SUE: 1.47 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.47 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=20
EPS next Year (2026-12-31): EPS=2.48 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+20.1% | Growth Revenue=+12.7%

Additional Sources for DXCM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle